William Earnest
Psychiatric/Mental Health · Montgomery, ALNPI 1184230377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,375, 3.4 times the $406 reported in 2021.
Across 286 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$990
- AbbVie$988
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$685
- Otsuka America Pharmaceutical, Inc.$507
- Lundbeck LLC$475
- Takeda Pharmaceuticals U.S.A., Inc.$474
- plus $1K from 8 others
What the payments were for
- Food & beverage$5,185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 48 | $990 |
| AbbVie | 85 | $988 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $685 |
| Otsuka America Pharmaceutical, Inc. | 25 | $507 |
| Lundbeck LLC | 20 | $475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $474 |
| Axsome Therapeutics, Inc. | 17 | $343 |
| Teva Pharmaceuticals USA, Inc. | 11 | $176 |
| Neurocrine Biosciences, Inc. | 8 | $167 |
| Vanda Pharmaceuticals Inc. | 4 | $142 |
| Johnson & Johnson | 4 | $90 |
| Bausch Health US, LLC | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
How this compares
$5,185 in reported general payments places this provider in the 80th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 17 | $29,014 |
| VraylarCariprazine Hcl | 17 | $27,449 |
| FanaptIloperidone | 16 | $13,494 |
| TrintellixVortioxetine Hydrobromide | 23 | $10,178 |
| Duloxetine Hcl | 114 | $2,040 |
| Lurasidone Hcl | 27 | $1,760 |
| Quetiapine Fumarate | 120 | $1,651 |
| Escitalopram Oxalate | 138 | $1,581 |
| Hydroxyzine Hcl | 102 | $1,559 |
| Sertraline Hcl | 232 | $1,399 |
| Atomoxetine Hcl | 12 | $1,132 |
| Buspirone Hcl | 102 | $1,118 |
| Lamotrigine | 100 | $1,111 |
| Aripiprazole | 39 | $836 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $507 | $29,01417 claims |
| AbbVieVraylar | $988 | $27,44917 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $142 | $13,49416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $474 | $10,17823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Montgomery
- Laura GrahamMontgomery$80K
- Hunter HutchisonMontgomery$14K
- Deangelo CooperMontgomery$9K
- Holli HosfordMontgomery$7K
- Jared KnightingMontgomery$5K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.